DK3347015T3 - Fremgangsmåder til diagnosticering og behandling af adfærdsforstyrrelser - Google Patents
Fremgangsmåder til diagnosticering og behandling af adfærdsforstyrrelser Download PDFInfo
- Publication number
- DK3347015T3 DK3347015T3 DK16767115.5T DK16767115T DK3347015T3 DK 3347015 T3 DK3347015 T3 DK 3347015T3 DK 16767115 T DK16767115 T DK 16767115T DK 3347015 T3 DK3347015 T3 DK 3347015T3
- Authority
- DK
- Denmark
- Prior art keywords
- diagnosing
- methods
- behavioral disorders
- treating behavioral
- treating
- Prior art date
Links
- 230000003542 behavioural effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562215636P | 2015-09-08 | 2015-09-08 | |
| US201562215628P | 2015-09-08 | 2015-09-08 | |
| US201562215673P | 2015-09-08 | 2015-09-08 | |
| US201562215633P | 2015-09-08 | 2015-09-08 | |
| PCT/US2016/050580 WO2017044502A1 (en) | 2015-09-08 | 2016-09-07 | Methods of diagnosing and treating conduct disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3347015T3 true DK3347015T3 (da) | 2021-12-06 |
Family
ID=56943962
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16767115.5T DK3347015T3 (da) | 2015-09-08 | 2016-09-07 | Fremgangsmåder til diagnosticering og behandling af adfærdsforstyrrelser |
| DK16771034.2T DK3347016T3 (da) | 2015-09-08 | 2016-09-07 | Diagnosticering og behandling af angstlidelse |
| DK16767112.2T DK3347013T3 (da) | 2015-09-08 | 2016-09-07 | Ikke-selektive metabotropiske glutamatreceptoraktivatorer til behandling af opmærksomhedsforstyrrelse og 22q-syndrom |
| DK16767114.8T DK3347014T3 (da) | 2015-09-08 | 2016-09-07 | Fremgangsmåder til diagnosticering og behandling af Tourettes syndrom |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16771034.2T DK3347016T3 (da) | 2015-09-08 | 2016-09-07 | Diagnosticering og behandling af angstlidelse |
| DK16767112.2T DK3347013T3 (da) | 2015-09-08 | 2016-09-07 | Ikke-selektive metabotropiske glutamatreceptoraktivatorer til behandling af opmærksomhedsforstyrrelse og 22q-syndrom |
| DK16767114.8T DK3347014T3 (da) | 2015-09-08 | 2016-09-07 | Fremgangsmåder til diagnosticering og behandling af Tourettes syndrom |
Country Status (12)
| Country | Link |
|---|---|
| US (12) | US20170087139A1 (da) |
| EP (9) | EP4342493A2 (da) |
| JP (8) | JP7152306B2 (da) |
| CN (7) | CN108348518A (da) |
| AU (8) | AU2016318775B2 (da) |
| CA (5) | CA2997187C (da) |
| DK (4) | DK3347015T3 (da) |
| ES (4) | ES2876898T3 (da) |
| HK (4) | HK1258446A1 (da) |
| IL (10) | IL290993B2 (da) |
| SG (1) | SG10202012842SA (da) |
| WO (4) | WO2017044497A1 (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2686300T3 (es) | 2010-08-24 | 2018-10-17 | The Children's Hospital Of Philadelphia | Asociación de variaciones genéticas raras recurrentes con el trastorno por déficit de atención e hiperactividad (TDAH) y procedimientos de uso de las mismas para el diagnóstico y tratamiento del mismo |
| WO2017044497A1 (en) * | 2015-09-08 | 2017-03-16 | The Children's Hospital Of Philadelphia | Methods of diagnosing and treating tourette syndrome |
| US20200143922A1 (en) * | 2016-06-03 | 2020-05-07 | Yale University | Methods and apparatus for predicting depression treatment outcomes |
| WO2018048868A1 (en) * | 2016-09-07 | 2018-03-15 | The Children's Hospital Of Philadelphia | Nonselective metabotropic glutamate receptor activators for treatment of anorexia nervosa and binge eating disorder |
| US11684617B2 (en) | 2017-04-19 | 2023-06-27 | The Children's Hospital Of Philadelphia | Methods of diagnosing and treating ADHD in biomarker positive subjects |
| WO2018209328A1 (en) * | 2017-05-11 | 2018-11-15 | Miwa Julie M | Compositions and methods for treating lynx2 disorders |
| CN107483425B (zh) * | 2017-08-08 | 2020-12-18 | 北京盛华安信息技术有限公司 | 基于攻击链的复合攻击检测方法 |
| SG11202006813TA (en) * | 2018-01-18 | 2020-08-28 | Childrens Hospital Philadelphia | Fasoracetam crystalline forms |
| TW201932453A (zh) * | 2018-01-18 | 2019-08-16 | 美商艾維基因醫學股份有限公司 | 法索西坦(fasoracetam)之固體型態 |
| KR102250063B1 (ko) * | 2019-06-14 | 2021-05-12 | 한국생명공학연구원 | 뚜렛증후군의 원인 유전자를 동정하는 방법 |
| CN110955751A (zh) * | 2019-11-13 | 2020-04-03 | 广州供电局有限公司 | 工作票文本去重方法、装置、系统及计算机存储介质 |
| CA3170698A1 (en) * | 2020-09-21 | 2022-03-24 | Reveragen Biopharma, Inc. | Vamorolone for the treatment of muscular dystrophy |
| WO2022065518A1 (ja) * | 2020-09-23 | 2022-03-31 | 国立大学法人京都大学 | 神経突起伸長促進剤 |
| CN117594119A (zh) * | 2024-01-17 | 2024-02-23 | 北京大学第六医院 | 用于预测帕罗西汀或其药用盐对抑郁或焦虑症患者疗效的装置 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002067931A1 (en) * | 2001-02-23 | 2002-09-06 | Johns Hopkins University | Treatment of tics, tremors and related disorders |
| CA2471198A1 (en) | 2001-12-20 | 2003-07-03 | Merck & Co., Inc. | Identification of novel polymorphic sites in the human mglur8 gene and uses thereof |
| JP2007530591A (ja) | 2004-03-25 | 2007-11-01 | スミスクライン・ビーチャム・コーポレイション | 双極性障害を治療するための、ｎｋ３アンタゴニストの使用 |
| AU2007223036A1 (en) | 2006-03-08 | 2007-09-13 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| TW200819458A (en) | 2006-06-23 | 2008-05-01 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
| EP2118320A4 (en) | 2007-02-06 | 2010-05-19 | Genizon Biosciences Inc | GENE CARD OF HUMAN GENES ASSOCIATED WITH HYPERACTIVITY ATTENTION DEFICIT DISORDER (ADHD) |
| WO2008136996A2 (en) | 2007-04-30 | 2008-11-13 | The Ohio State University Research Foundation | Polymorphisms in genes affecting ace-related disorders and uses thereof |
| US20090176740A1 (en) | 2007-11-30 | 2009-07-09 | Phillips Ii Dauglas James | Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine |
| WO2009105718A1 (en) | 2008-02-20 | 2009-08-27 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism |
| WO2010057132A1 (en) | 2008-11-14 | 2010-05-20 | The Children's Hospital Of Philadelphia | Genetic alterations associated with schizophrenia and methods of use thereof for the diagnosis and treatment of the same |
| US20110311512A1 (en) | 2008-11-14 | 2011-12-22 | Hakon Hakonarson | Genetic Variants Underlying Human Cognition and Methods of Use Thereof as Diagnostic and Therapeutic Targets |
| EP2470527A4 (en) | 2009-08-20 | 2013-02-27 | Merck Sharp & Dohme | BENZOTRIAZOLE D ETHER DERIVATIVES |
| US8714471B2 (en) * | 2010-07-29 | 2014-05-06 | Brady Worldwide, Inc. | Friction core brake |
| ES2686300T3 (es) | 2010-08-24 | 2018-10-17 | The Children's Hospital Of Philadelphia | Asociación de variaciones genéticas raras recurrentes con el trastorno por déficit de atención e hiperactividad (TDAH) y procedimientos de uso de las mismas para el diagnóstico y tratamiento del mismo |
| US20130225623A1 (en) | 2010-10-27 | 2013-08-29 | Mount Sinai School Of Medicine | Methods of Treating Psychiatric or Neurological Disorders with MGLUR Antagonists |
| WO2013006857A1 (en) | 2011-07-07 | 2013-01-10 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism |
| US20130143867A1 (en) * | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| AU2013305580A1 (en) * | 2012-08-23 | 2015-04-09 | Stuart L. Weg | Anxiolytic composition, formulation and method of use |
| US9346239B2 (en) | 2012-09-26 | 2016-05-24 | Eastman Kodak Company | Method for providing patterns of functional materials |
| WO2014152965A2 (en) | 2013-03-14 | 2014-09-25 | The Children's Hospital Of Philadelphia | Schizophrenia-associated genetic loci identified in genome wide association studies and use thereof as novel therapeutic targets |
| EP3149211A1 (en) | 2014-05-30 | 2017-04-05 | The Children's Hospital of Philadelphia | Genetic alterations associated with autism and autistic phenotype and methods of diagnosing and treating autism |
| US11219617B2 (en) | 2014-05-30 | 2022-01-11 | The Children's Hospital Of Philadelphia | Methods of diagnosing and treating autism |
| KR102232583B1 (ko) | 2015-01-08 | 2021-03-26 | 삼성전자주식회사 | 전자장치 및 전자장치의 웹 재현 방법 |
| EP3307913A4 (en) | 2015-06-15 | 2019-03-27 | The Children's Hospital of Philadelphia | METHOD FOR DIAGNOSIS AND TREATMENT OF AUTISM |
| WO2017044497A1 (en) | 2015-09-08 | 2017-03-16 | The Children's Hospital Of Philadelphia | Methods of diagnosing and treating tourette syndrome |
-
2016
- 2016-09-07 WO PCT/US2016/050573 patent/WO2017044497A1/en active Application Filing
- 2016-09-07 CN CN201680065080.6A patent/CN108348518A/zh active Pending
- 2016-09-07 US US15/258,924 patent/US20170087139A1/en not_active Abandoned
- 2016-09-07 ES ES16771034T patent/ES2876898T3/es active Active
- 2016-09-07 EP EP24153857.8A patent/EP4342493A2/en active Pending
- 2016-09-07 AU AU2016318775A patent/AU2016318775B2/en active Active
- 2016-09-07 WO PCT/US2016/050559 patent/WO2017044491A1/en active Application Filing
- 2016-09-07 EP EP16771034.2A patent/EP3347016B1/en active Active
- 2016-09-07 CN CN202211219188.XA patent/CN115919852A/zh active Pending
- 2016-09-07 CA CA2997187A patent/CA2997187C/en active Active
- 2016-09-07 EP EP22156141.8A patent/EP4023222A1/en active Pending
- 2016-09-07 EP EP16767112.2A patent/EP3347013B1/en active Active
- 2016-09-07 DK DK16767115.5T patent/DK3347015T3/da active
- 2016-09-07 IL IL290993A patent/IL290993B2/en unknown
- 2016-09-07 DK DK16771034.2T patent/DK3347016T3/da active
- 2016-09-07 CA CA3225374A patent/CA3225374A1/en active Pending
- 2016-09-07 IL IL300474A patent/IL300474A/en unknown
- 2016-09-07 DK DK16767112.2T patent/DK3347013T3/da active
- 2016-09-07 SG SG10202012842SA patent/SG10202012842SA/en unknown
- 2016-09-07 WO PCT/US2016/050580 patent/WO2017044502A1/en active Application Filing
- 2016-09-07 AU AU2016318786A patent/AU2016318786B2/en active Active
- 2016-09-07 US US15/258,828 patent/US9884057B2/en active Active
- 2016-09-07 CN CN202310713811.5A patent/CN116919961A/zh active Pending
- 2016-09-07 DK DK16767114.8T patent/DK3347014T3/da active
- 2016-09-07 JP JP2018512234A patent/JP7152306B2/ja active Active
- 2016-09-07 JP JP2018512235A patent/JP7027308B2/ja active Active
- 2016-09-07 JP JP2018512296A patent/JP7281280B2/ja active Active
- 2016-09-07 AU AU2016318785A patent/AU2016318785B2/en active Active
- 2016-09-07 EP EP21201653.9A patent/EP3964213B1/en active Active
- 2016-09-07 ES ES16767112T patent/ES2909329T3/es active Active
- 2016-09-07 CN CN201680065041.6A patent/CN108495630A/zh active Pending
- 2016-09-07 CN CN202310713998.9A patent/CN116919962A/zh active Pending
- 2016-09-07 AU AU2016318780A patent/AU2016318780B2/en active Active
- 2016-09-07 ES ES16767114T patent/ES2897953T3/es active Active
- 2016-09-07 ES ES16767115T patent/ES2898932T3/es active Active
- 2016-09-07 EP EP21170586.8A patent/EP3922249B1/en active Active
- 2016-09-07 EP EP21201628.1A patent/EP3977996B1/en active Active
- 2016-09-07 CA CA2997188A patent/CA2997188A1/en active Pending
- 2016-09-07 JP JP2018512253A patent/JP7281279B2/ja active Active
- 2016-09-07 CN CN201680065071.7A patent/CN108601776A/zh active Pending
- 2016-09-07 US US15/258,969 patent/US11179378B2/en active Active
- 2016-09-07 US US15/258,977 patent/US11173153B2/en active Active
- 2016-09-07 CA CA2997189A patent/CA2997189A1/en active Pending
- 2016-09-07 CA CA2997191A patent/CA2997191A1/en active Pending
- 2016-09-07 EP EP16767115.5A patent/EP3347015B1/en active Active
- 2016-09-07 WO PCT/US2016/050581 patent/WO2017044503A1/en active Application Filing
- 2016-09-07 CN CN201680065020.4A patent/CN108348517B/zh active Active
- 2016-09-07 IL IL303605A patent/IL303605A/en unknown
- 2016-09-07 EP EP16767114.8A patent/EP3347014B1/en active Active
-
2017
- 2017-12-21 US US15/850,307 patent/US10869861B2/en active Active
-
2018
- 2018-02-26 IL IL257744A patent/IL257744B/en unknown
- 2018-02-26 IL IL257746A patent/IL257746B/en unknown
- 2018-02-26 IL IL257747A patent/IL257747B/en unknown
- 2018-02-28 IL IL257785A patent/IL257785B/en unknown
-
2019
- 2019-01-16 HK HK19100751.8A patent/HK1258446A1/zh unknown
- 2019-01-16 HK HK19100745.7A patent/HK1258373A1/zh unknown
- 2019-01-16 HK HK19100752.7A patent/HK1258447A1/zh unknown
- 2019-01-16 HK HK19100753.6A patent/HK1258448A1/zh unknown
-
2020
- 2020-03-04 US US16/809,045 patent/US11298347B2/en active Active
- 2020-12-17 US US17/125,164 patent/US20210205288A1/en active Pending
-
2021
- 2021-10-27 US US17/511,795 patent/US11806340B2/en active Active
- 2021-10-28 US US17/512,827 patent/US11806341B2/en active Active
-
2022
- 2022-02-16 JP JP2022022123A patent/JP2022078104A/ja active Pending
- 2022-02-28 IL IL290994A patent/IL290994A/en unknown
- 2022-02-28 IL IL290992A patent/IL290992B2/en unknown
- 2022-02-28 IL IL290985A patent/IL290985A/en unknown
- 2022-04-06 US US17/714,276 patent/US20220296582A1/en active Pending
- 2022-05-05 AU AU2022203039A patent/AU2022203039A1/en active Pending
- 2022-06-20 AU AU2022204324A patent/AU2022204324A1/en active Pending
- 2022-06-21 AU AU2022204355A patent/AU2022204355A1/en active Pending
- 2022-07-11 AU AU2022205142A patent/AU2022205142A1/en active Pending
- 2022-09-29 JP JP2022155714A patent/JP2023011558A/ja active Pending
- 2022-12-09 JP JP2022197117A patent/JP2023051937A/ja active Pending
- 2022-12-09 JP JP2022197128A patent/JP2023036671A/ja active Pending
-
2023
- 2023-10-30 US US18/497,338 patent/US20240100036A1/en active Pending
- 2023-10-30 US US18/497,386 patent/US20240075022A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3347015T3 (da) | Fremgangsmåder til diagnosticering og behandling af adfærdsforstyrrelser | |
| DK3206493T3 (da) | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser | |
| DK3374163T3 (da) | Additivfremstillingsanordning, system og fremgangsmåde | |
| DK3280441T3 (da) | Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3227336T3 (da) | Anti-CD79b-antistoffer og fremgangsmåder til anvendelse | |
| DK3888658T3 (da) | Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil | |
| DK3114540T3 (da) | Neuralt netværk og fremgangsmåder til træning af neuralt netværk | |
| DK3185876T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser | |
| DK3265947T3 (da) | Fremgangsmåde og system til kryptering | |
| DK3201351T3 (da) | Kaloriefrie sødestoffer og fremgangsmåder til syntetisering | |
| DK3286311T3 (da) | Fremgangsmåde til behandling af maligniteter | |
| DK3250210T3 (da) | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3319612T3 (da) | Oxysteroler og fremgansmåder til anvendelse derfor | |
| DK3215147T3 (da) | Neurodæmpende norketamin-forbindelser og fremgangsmåder | |
| BR112016026939A2 (pt) | aparelho e método. | |
| DK3339479T3 (da) | Elektrolyseindretning og elektrolysefremgangsmåde | |
| DK3285782T3 (da) | Fremgangsmåder til vævsreparation og -regenerering | |
| DK3633683T3 (da) | Fremgangsmåde til at fusionere og komprimere kompakte tori | |
| DK3539469T3 (da) | System og fremgangsmåde til overvågning af bækkenbundsmusklerne | |
| DK3174489T3 (da) | Metode og anordning til at læsse | |
| BR112016027102A2 (pt) | método e aparelho | |
| DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
| DK3110446T3 (da) | Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme | |
| KR20180084959A (ko) | 파면 분석을 위한 디바이스 및 방법 |